ImmunoGen, Inc. (NASDAQ:IMGN) was the target of a significant growth in short interest during the month of March. As of March 29th, there was short interest totalling 13,813,907 shares, a growth of 24.1% from the March 15th total of 11,130,866 shares. Currently, 9.4% of the shares of the stock are short sold. Based on an average daily volume of 2,850,291 shares, the days-to-cover ratio is currently 4.8 days.

Shares of IMGN opened at $2.72 on Thursday. The company has a current ratio of 3.95, a quick ratio of 3.95 and a debt-to-equity ratio of 0.19. The company has a market cap of $398.93 million, a P/E ratio of -2.31 and a beta of 2.23. ImmunoGen has a 1 year low of $2.27 and a 1 year high of $12.31.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, February 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.05. The company had revenue of $13.79 million for the quarter, compared to the consensus estimate of $12.42 million. ImmunoGen had a negative net margin of 311.94% and a negative return on equity of 599.63%. ImmunoGen’s revenue was down 65.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) earnings per share. On average, equities analysts predict that ImmunoGen will post -1.27 EPS for the current year.

In related news, CEO Mark J. Enyedy sold 51,070 shares of the company’s stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $5.60, for a total transaction of $285,992.00. Following the transaction, the chief executive officer now owns 483,768 shares of the company’s stock, valued at $2,709,100.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Thomas Ryll sold 11,495 shares of the company’s stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $5.60, for a total transaction of $64,372.00. Following the transaction, the vice president now directly owns 87,184 shares in the company, valued at approximately $488,230.40. The disclosure for this sale can be found here. 4.44% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of IMGN. Two Sigma Investments LP raised its stake in ImmunoGen by 2,747.6% during the fourth quarter. Two Sigma Investments LP now owns 1,106,879 shares of the biotechnology company’s stock worth $5,313,000 after purchasing an additional 1,068,008 shares during the period. BlackRock Inc. raised its stake in ImmunoGen by 10.0% during the third quarter. BlackRock Inc. now owns 11,481,977 shares of the biotechnology company’s stock worth $108,733,000 after purchasing an additional 1,045,627 shares during the period. Opaleye Management Inc. purchased a new position in ImmunoGen during the fourth quarter worth approximately $4,900,000. Deutsche Bank AG raised its stake in ImmunoGen by 154.6% during the fourth quarter. Deutsche Bank AG now owns 1,242,243 shares of the biotechnology company’s stock worth $5,962,000 after purchasing an additional 754,366 shares during the period. Finally, Sofinnova Investments Inc. purchased a new position in ImmunoGen during the fourth quarter worth approximately $2,146,000. 82.88% of the stock is currently owned by institutional investors.

Several brokerages recently issued reports on IMGN. Piper Jaffray Companies downgraded shares of ImmunoGen from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $13.00 to $2.50 in a research note on Friday, March 1st. Leerink Swann downgraded shares of ImmunoGen from an “outperform” rating to a “market perform” rating in a research note on Friday, March 1st. Jefferies Financial Group downgraded shares of ImmunoGen from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. Svb Leerink downgraded shares of ImmunoGen from an “outperform” rating to a “market perform” rating in a research note on Monday, March 4th. Finally, BidaskClub downgraded shares of ImmunoGen from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 22nd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. ImmunoGen has an average rating of “Hold” and an average target price of $7.17.

COPYRIGHT VIOLATION NOTICE: “Short Interest in ImmunoGen, Inc. (IMGN) Expands By 24.1%” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/short-interest-in-immunogen-inc-imgn-expands-by-24-1/2953743.html.

About ImmunoGen

ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.

Recommended Story: Bull Market

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.